Stomach implant for long-term erythropoietin expression in rats

Blood

Volumn 92, Issue 3, 1998, Pages 888-893

  Lejnieks, Daniel V ^a   Ramesh, N ^a   Lau, Stella ^a   Osborne, William R A ^a  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ERYTHROPOIETIN;

ANEMIA; ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; AUTOTRANSPLANTATION; ERYTHROPOIESIS; GENE TRANSFER; GRAFT SURVIVAL; HEMATOCRIT; HORMONE RELEASE; NONHUMAN; PRIORITY JOURNAL; RAT;

EID: 0032147041     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v92.3.888     Document Type: Article

References (54)

1. Koury MJ, Bondurant MC: The molecular mechanism of erythropoietin action. Eur J Biochem 210:649, 1992
2. Spivak JL: Hematology/Oncology Clinics of North America. Erythropoietin: Basic and clinical aspects. Hematol Oncol Clin North Am 8:1043, 1994
3. Lin F-K, Suggs S, Lin C-H, Browne JK, Smalling R, Egrie JC, Chen KK, Fox GM, Martin F, Stabinsky Z, Bradrawi SM, Lai P-H, Goldwasser E: Cloning and expression of the human erythropoietin gene. Proc Natl Acad Sci USA 82:7580, 1985
4. Jacobs K, Shoemaker CB, Rudersdorf R, Neill SD, Kaufman RJ, Mufson A, Seehra J, Jones SS, Hewick R, Fritsch EF, Kawakita M, Shimizu T, Miyake T: Isolation and characterization of genomic and cDNA clones of human erythropoietin. Nature 313:806, 1985
5. Wen D, Boissel J-PR, Tracy TE, Gruninger RH, Mulcahy LS, Czelusniak J, Goodman M, Bunn HF: Erythropoietin structure-function relationships: High degree of sequence homology among mammals. Blood 82:1507, 1993
6. Eschbach JW, Egrie JC, Downing MR, Brown JK, Adamson JW: Correction of the anemia of end-stage renal disease with recombinant human erythropoietin. Results of a combined phase I and II clinical trial. N Engl J Med 316:73, 1987
7. Koury ST, Bondurant MC, Koury MJ, Semenza GL: Localization of cells producing erythropoietin in murine liver by in situ hybridization. Blood 77:2497, 1991
8. Schuster SJ, Koury ST, Bohrer M, Salceda S, Caro J: Cellular sites of extrarenal erythropoietin production in anaemic rats. Br J Haematol 81:153, 1992
9. Beck I, Weinmann R, Caro J: Characterization of hypoxia-response enhancer in the human erythropoietin gene shows presence of hypoxia-inducible 120-Kd nuclear DNA-binding protein in erythropoietin-producing and nonproducing cells. Blood 82:704, 1993
10. Blanchard KL, Acquaviva AM, Galson DL, Bunn HF: Hypoxia induction of the human erythropoietin gene: Cooperation between the promoter and enhancer, each of which contains steroid receptor response elements. Mol Cell Biol 12:5373, 1992
11. Firth JD, Ebert BL, Pugh SW, Ratcliffe PJ: Oxygen-regulated control elements in the phosphoglycerate kinase 1 and lactate dehydrogenase A gene: Similarities with the erythropoietin 3′ enhancer. Proc Natl Acad Sci USA 91:6496, 1994
12. Madan A, Curtin PT: A 24-base-pair sequence 3′ to the human erythropoietin gene contains a hypoxia-responsive transcriptional enhancer. Proc Natl Acad Sci USA 90:3928, 1993
13. Maxwell PH, Pugh CW, Ratcliffe PJ: Inducible operation of the erythropoeitin 3′ enhancer in multiple cell lines: Evidence for a widespread oxygen-sensing mechanism. Proc Natl Acad Sci USA 90:2423, 1993
14. Semenza GL, Roth PH, Fang HM, Wang GL: Transcriptional regulation of genes encoding glycolytic enzymes by hypoxia-inducible factor 1. J Biol Chem 269:23757, 1994
15. Wang GL, Semenza GL: General involvement of hypoxia-inducible factor 1 in transcriptional response to hypoxia. Proc Natl Acad Sci USA 90:4304, 1993
16. Wang GL, Semenza GL: Characterization of hypoxia-inducible factor 1 and regulation of DNA binding activity by hypoxia. J Biol Chem 268:21513, 1993
17. Miller AD: Human gene therapy cornes of age. Nature 357:455, 1992
18. Morgan RA, Anderson WF: Human gene therapy. Annu Rev Biochem 62:191, 1993
19. Mulligan RC: The basic science of gene therapy. Science 260:926, 1993
20. Kohn DB: The current status of gene therapy using hematopoietic stem cells. Curr Opin Pediatr 7:56, 1995
21. Muzyczka N: Use of adeno-associated virus as a general transduction vector for mammalian cells, in Muzyczka N (ed): Current Topics in Microbiology and Immunology. Viral Expression Vectors (vol 158). New York, NY, Springer-Verlag, 1992, p 97
22. Samulski RJ: Adeno-asssociated virus: Integration at a specific chromosomal locus. Curr Opin Genet Dev 3:74, 1993
23. Kessler PD, Podsaloff GM, Chen X, McQuiston SA, Colosi PC, Matelis LA, Kurtzman GJ, Byrne BJ: Gene delivery to skeletal muscle results in sustained expression and systemic delivery of a therapeutic protein. Proc Natl Acad Sci USA 93:14082, 1996
24. Kaplitt MG, Leone P, Samulski RJ, Xiao X, Pfaff DW, O'Malley KL, During MJ: Long-term gene expression and phenotypic correction using adeno-associated virus vectors in mammalian brain. Nat Genet 8:148, 1994
25. Snyder RO, Miao CH, Patijn GA, Spratt SK, Danos O, Nagy D, Gown AM, Winther B, Meuse L, Cohen LK, Thompson AR, Kay MA: Persistent and therapeutic concentrations of human factor IX in mice after hepatic gene transfer of recombinant AAV vectors. Nat Genet 16:270, 1997
26. Adam MA, Ramesh N, Miller AD, Osborne WRA: Internal initiation of translation in retroviral vectors carrying picornavirus 5′ nontranslated regions. J Virol 65:4985, 1991
27. Morgan RA, Couture L, Elroy-Stein O, Ragheb J, Moss B, Anderson WA: Retroviral vectors containing putative internal ribosome entry sites: Development of a polycistronic gene transfer system and applications to human gene therapy. Nucleic Acids Res 20:1293, 1992
28. Ramesh N, Kim S-T, Wei MQ, Khalighi M, Osborne WRA: High-titer bicistronic vectors employing foot-and-mouth disease virus internal ribosome entry site. Nucleic Acids Res 24:2697, 1996
29. Ramesh N, Lau S, Palmer TD, Storb R, Osborne WRA: High-level human adenosine deaminase expression in dog skin fibroblasts is not sustained following transplantation. Hum Gene Ther 4:3, 1993
30. Palmer TD, Rosman GJ, Osborne WRA, Miller AD: Genetically- modified skin fibroblasts persist long after transplantation but gradually inactivate introduced genes. Proc Natl Acad Sci USA 88:1330, 1991
31. Barr E, Tripathy S, Leiden JM: Genetically modified myoblasts for the treatment of erythropoietin-responsive anemias. J Cell Biochem 18:DZ012, 1994 (suppl 18A)
32. Hamamori Y, Samal B, Tian J, Kedes L: Myoblast transfer of human erythropoietin gene in a mouse model of renal failure. J Clin Invest 95:1808, 1995
33. Naffakh N, Pinset C, Montarras D, Paulin D, Danos O, Heard JM: Long-term secretion of therapeutic proteins from genetically modified skeletal muscles. Hum Gene Ther 7:11, 1996
34. Shull RM, Lu X, McEntee MF, Bright RM, Pepper KA, Kohn DB: Myoblast gene therapy in canine mucopolysaccharidosis I: Abrogation by an immune response to alpha-L-iduronidase. Hum Gene Ther 7:1595, 1996
35. Tripathy SK, Svensson EC, Black BH, Goldwasser G, Margalith M, Hobart PM, Leiden JM: Long-term expression of erythropoietin in the systemic circulation of mice after intramuscular injection of a plasmid DNA vector. Proc Natl Acad Sci USA 93:10876, 1996
36. Clowes MM, Lynch CM, Miller AD, Miller DG, Osborne WRA, Clowes AW: Long-term biological response of injured rat carotid artery seeded with smooth muscle cells expressing retrovirally introduced human genes. J Clin Invest 93:644, 1994
37. Geary RL, Clowes AW, Lau S, Vergel S, Dale DC, Osborne WRA: Gene transfer in baboons using prosthetic vascular grafts seeded with retrovirally-transduced smooth muscle cells: A model for local and systemic gene therapy. Hum Gene Ther 5:1213, 1994
38. Osborne WRA, Ramesh N, Lau S, Clowes MM, Dale DC, Clowes AW: Gene therapy for long-term expression of erythropoietin in rats. Proc Natl Acad Sci USA 92:8055, 1995
39. Ohno T, Gordon D, San H, Pompili MJ, Nabel GJ, Nabel EG: Gene therapy for vascular smooth muscle cell proliferation after arterial injury. Science 265:781, 1994
40. Plautz G, Nabel EG, Nabel GJ: Introduction of vascular smooth muscle cells expressing recombinant genes in vivo. Circulation 83:578, 1991
41. Lejnieks DV, Han SW, Ramesh N, Lau S, Osborne WRA: Granulocyte colony-stimulating factor expression from transduced vascular smooth muscle cells provides sustained neutrophil increases in rats. Hum Gene Ther 7:1431, 1996
42. Lynch CM, Clowes MM, Osborne WRA, Clowes AW, Miller AD: Long-term expression of human adenosine deaminase in vascular smooth muscle cells of rats: A model for gene therapy. Proc Natl Acad Sci USA 89:1138, 1992
43. Miller AD, Rosman GJ: Improved retroviral vectors for gene transfer and expression. Biotechniques 7:980, 1989
44. Hock RA, Miller AD, Osborne WRA: Expression of human adenosine deaminase from various strong promoters after gene transfer into human hematopoietic cell lines. Blood 74:876, 1989
45. Miller AD, Buttimore C: Redesign of retrovirus packaging cell lines to avoid recombination to helper virus production. Mol Cell Biol 6:2895, 1986
46. Schalm OW, Jain NC, Carroll EJ: Veterinary Hematology (ed 3). Philadelphia, PA, Lea and Febiger, 1975
47. Semenza GL, Nejfelt MK, Chi SM, Antonarakis SE: Hypoxia-inducible nuclear factors bind to an enhancer element located 3′ to the human erythropoietin gene. Proc Natl Acad Sci USA 88:5680, 1991
48. Spivak JL, Pham T, Isaacs M, Hankins WD: Erythropoietin is both a mitogen and a survival factor. Blood 77:1228, 1991
49. Axelrod L: Corticosteroid therapy, in Becker EL (ed): Principles and Practice of Endocrinology and Metabolism. Philadelphia, PA, Lippincott, 1995, p 695
50. Fletcher DS, Osinga D, Bonney RJ: Role of polymorphonuclear leukocytes in connective tissue breakdown during the reverse Arthus reaction. Biochem Pharmacol 35:2601, 1986
51. Weber CR, Griffin JM: Evaluation of dexamethasone for reducing postoperative edema and inflammatory response after orthognathic surgery. J Oral Maxillofac Surg 52:35, 1994
52. Madan A, Lin C, Hatch SL, Curtin PT: Regulated basal, inducible, and tissue-specific human erythropoietin gene expression in transgenic mice requires multiple cis DNA sequences. Blood 85:2735, 1995
53. Tapscott SJ, Miller AD, Olsen JM, Berger MS, Groudine M, Spence AM: Gene therapy of rat 9L gliosarcoma tumors by transduction with selectable genes does not require drug selection. Proc Natl Acad Sci USA 91:8185, 1994
54. Riddel SR, Elliott M, Lewinsohn DA, Gilbert MJ, Wilson L, Manley SA, Lupton SD, Overell RW, Reynolds TC, Corey L, Greenberg PD: T-cell mediated rejection of gene-modified HIV-specific cytotoxic T lymphocytes in HIV patients. Nat Med 2:216, 1996